#United States #Patient Safety #NABP #Compounded Medications #Mount Prospect

NABP Takes Bold Step to Improve Patient Safety in Compounding

The National Association of Boards of Pharmacy (NABP) has taken an important initiative aimed at addressing long-standing gaps in the tracking and reporting of adverse events related to compounded medications. On July 29, 2026, NABP announced its plans to create a national adverse event reporting clearinghouse, which will serve as a vital resource for gathering reports of patient harm resulting from compounded drug products. This new system is set to foster better communication between state pharmacy boards and the U.S. Food and Drug Administration (FDA).

The Need for Change

Historically, compounded medications produced by 503A pharmacies have not been subject to the same rigorous federal adverse event reporting requirements that apply to FDA-registered drug manufacturers and 503B outsourcing facilities. This omission has created a significant vulnerability in patient safety, as incidents of harm caused by compounded drugs often go undocumented. The NABP aims to rectify this deficiency by establishing a national system that will ensure adverse events are communicated effectively across jurisdictions.

Lemrey "Al" Carter, PharmD, MS, RPh, the executive director of NABP, emphasized the gravity of this issue, stating, "When a patient is harmed by a compounded medication, that information too often stays in one state, or never surfaces at all. We cannot protect patients from risks regulators cannot see."

Creating a Unified Reporting Mechanism

In its efforts to combat this problem, the NABP highlighted the challenges posed by the current regulatory framework. The rapid growth in compounded GLP-1 medications and new business models have stretched the existing system, originally designed for small-scale, patient-specific compounding, to its limits. The proposed adverse event reporting clearinghouse is intended to rectify these discrepancies and streamline the flow of safety information among regulators.

The clearinghouse will function as a centralized platform that collects reports of adverse effects from compounded medications. By enabling state boards of pharmacy and the FDA to share information, the NABP hopes to enhance the monitoring of safety issues and allow for cross-state insights that can potentially protect patients nationwide.

Plans for Implementation

In the coming months, NABP plans to convene meetings with pharmacy boards, the FDA, and other stakeholders within the industry to collaboratively define the structure and governance of this new clearinghouse. This initiative aims to develop clear connections to existing state and federal reporting programs, ensuring that the clearinghouse is integrated into current safety infrastructures.

In addition to this clearinghouse, the NABP is committed to implementing several other safety measures, including:

• - Expanding real-time information sharing within current legal limitations,
• - Establishing model standards for the verification of bulk drug substances used in compounding, and
• - Creating coordinated referral pathways among pharmacy boards, medical boards, and state attorneys general for cases that may cross jurisdictional boundaries.

A Commitment to Patient Safety

The NABP's initiative to establish the adverse event reporting clearinghouse represents a significant step toward filling vital gaps in America's patient safety net. By providing a central repository for information on adverse events, the NABP is not just protecting patients in individual states but fostering a nationwide collaborative approach to medication safety.

As patients increasingly rely on compounded medications, the importance of effective oversight and safety management has never been more critical. This initiative underscores NABP's commitment to safeguarding public health and enhancing patient safety in the ever-evolving landscape of pharmacy practice.

For further information, please contact the NABP media relations at [email protected]

Conclusion

In a world where the safety of compounded medications is paramount, the NABP's proposal stands to change the monitoring landscape dramatically. By prioritizing adverse event reporting, the association is working to ensure that health care professionals are better equipped to manage risks associated with compounded drugs, ultimately improving health outcomes for all patients.